BRAF and central nervous system cancer: In pediatric low-grade glioma, patients harboring the BRAF V600E mutation exhibited poor clinical outcomes after chemotherapy and radiotherapy with a 10-year PFS rate of 27% and 60.2% for the BRAF V600E wild type (19).